You are viewing a version of a model that has been updated. To access the latest version, and a more detailed display please go here.

DDMODEL00000044: Miltefosine PK in European and Indian pediatric and adult leishmaniasis patients

  public model
Short description:
A model for miltefosine PK in European adult cutaneous leishmaniasis and Indian pediatric and adult visceral leishmaniasis patients using allometric scaling
Original code
  • Optimal dosing of miltefosine in children and adults with visceral leishmaniasis.
  • Huitema AD, Beijnen JH, de Vries PJ
  • Antimicrobial agents and chemotherapy, 7/2012, Volume 56, Issue 7, pages: 3864-3872
  • Division of Infectious Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. thomasdorlo@gmail.com
  • Only anecdotal data are available on the pharmacokinetics (PK) of miltefosine in children suffering from visceral leishmaniasis (VL). While failure rates were higher in children with VL, steady-state concentrations appeared lower than those seen with adults. We hypothesized that the current linear dosage (in milligrams per kilogram of body weight) is too low for children and that a new dosing algorithm based on an appropriate body size model would result in an optimal exposure. A population PK analysis was performed on three historic pooled data sets, including Indian children, Indian adults, and European adults. Linear and allometric scaling of PK parameters by either body weight or fat-free mass (FFM) was evaluated for body size models. Based on the developed PK model, a dosing algorithm for miltefosine in children and adults was proposed and evaluated in silico. The population PK model employing allometric scaling fitted best to the pooled miltefosine data. Allometric scaling by FFM reduced between-subject variability, e.g., for drug clearance, from 49.6% to 32.1%. A new allometric miltefosine dosing algorithm was proposed. Exposure to miltefosine was lower in children than adults receiving 2.5 mg/kg/day: a C(max) of 18.8 ?g/ml was reached by 90% of adults and 66.7% of children. The allometric daily dose resulted in similar levels of exposure to miltefosine for adults and children. The use of a new allometric dosing algorithm for miltefosine in VL patients results in optimal exposure to miltefosine in both adults and children and might improve clinical outcome in children.
Thomas Dorlo
Annotations have not been checked.
This model is not certified.
  • Model owner: Thomas Dorlo
  • Submitted: Dec 11, 2015 10:54:23 AM
  • Last Modified: Jun 3, 2016 2:13:09 PM
Revisions
  • Version: 11 public model Download this version
    • Submitted on: Jun 3, 2016 2:13:09 PM
    • Submitted by: Thomas Dorlo
    • With comment: Updated model annotations.
  • Version: 8 public model Download this version
    • Submitted on: Dec 11, 2015 10:54:23 AM
    • Submitted by: Thomas Dorlo
    • With comment: Edited model metadata online.
 
Help